How Roche Diagnostics is transforming Alzheimer’s diagnosis with innovative blood-based biomarkers

Discover how Roche Diagnostics is transforming the diagnosis of Alzheimer’s disease with innovative blood-based biomarkers. In this interview, Cristiano Tunesi, the Neurology International Business Leader, discusses the Elecsys^® pTau tests and their role in early detection, including the Elecsys pTau181 blood test to rule out Alzheimer’s disease, which recently received CE approval, and the Elecsys pTau217, which can distinguish Alzheimer’s disease from other neurodegenerative disorders. He also addresses the challenges of integrating these tests into primary care and shares insights on Roche’s future innovations in neurology, which encompass Alzheimer’s, Parkinson’s disease, multiple sclerosis, and more.